II. Indications

  1. Emesis of central cause

III. Mechanism

  1. Centrally acting non-Phenothiazine Antiemetic
  2. Dopamine 2 Antagonist
    1. Active at the ChemoreceptorTrigger Zone in the Medulla of the Brainstem

IV. Dosing

  1. Adults
    1. Dose: 300 mg orally or 200 mg IM every 6 to 8 hours
  2. Child (15 to 41 kg)
    1. Dose: 100-200 mg orally three to four times daily
  3. Child (<15 kg): Avoid

V. Safety

  1. Pregnancy Category C
  2. Unknown safety in Lactation
  3. Reduce dose in renal dysfunction and older patients

VII. References

  1. Johnson (1993) Harriet Lane, Mosby, p. 521
  2. Hamilton (2020) Tarascon Pocket Pharmacopoeia

Images: Related links to external sites (from Bing)

Related Studies

Ontology: trimethobenzamide (C0077163)

Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH C100146
SnomedCT 14814001, 372657005
LNC LP19504-7, MTHU010019
English trimethobenzamide, trimethobenzamide [Chemical/Ingredient], TRIMETHOBENZAMIDE, Trimethobenzamide, Trimethobenzamide (product), Trimethobenzamide (substance)
Spanish trimetobenzamida (producto), trimetobenzamida (sustancia), trimetobenzamida

Ontology: Tigan (C0733768)

Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH C100146
English Tigan, tigan, Monarch brand of trimethobenzamide monohydrochloride